title: Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients 50 Years and Older with End-Stage Renal Disease and on Dialysis.
abstract: Patients with end-stage renal disease (ESRD) and on dialysis are at increased risk of pneumococcal disease. We evaluated the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) in this population. Eligible patients with ESRD and on dialysis were given a single dose of PCV13. The concentrations of serum antibodies against 13 pneumococcal capsular polysaccharides were measured at the baseline and at 2 and 12 months postvaccination. A response to the vaccine was defined as a ≥2-fold increase in antibody concentration from that at the baseline and an absolute postvaccination value of at least 1 μg/ml. Seventeen patients completed the study. Increases in the concentrations of antibodies to the vaccine serotype were demonstrated 2 months after vaccination. The geometric mean antibody concentrations at 12 months postvaccination declined by 38% to 72% compared to those measured at 2 months postvaccination. A response to at least 1 serotype in the vaccine was seen in all patients at both 2 and 12 months postvaccination. The overall rate of the response to each individual vaccine serotype varied between 23.5% and 94.1% at 2 months postvaccination and 23.5% and 65% at 12 months postvaccination. Pain at the injection site was the most common local reaction. Vaccination with PCV13 induces antibody responses to vaccine serotypes in patients with ESRD and on dialysis at 2 months postvaccination. However, the decline in antibody concentrations at 12 months postvaccination with a conjugate pneumococcal vaccine requires further study. (This study has been registered at ClinicalTrials.gov under registration no. NCT01974817.).
authors: Division of Infectious Diseases, Michigan State University, East Lansing, Michigan, USA.
authors: Subhashis
authors: S
authors: Mitra
authors: Division of Infectious Diseases, Michigan State University, East Lansing, Michigan, USA gary.stein@hc.msu.edu.
authors: Gary E
authors: GE
authors: Stein
authors: Department of Nephrology, Sparrow Hospital, Lansing, Michigan, USA.
authors: Shyam
authors: S
authors: Bhupalam
authors: Division of Infectious Diseases, Michigan State University, East Lansing, Michigan, USA.
authors: Daniel H
authors: DH
authors: Havlichek
mesh_terms: D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D005260:Female; D006801:Humans; D000071497:Immunogenicity, Vaccine; D007074:Immunoglobulin G / Q000097:blood; D007676:Kidney Failure, Chronic / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000276:immunology; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D006435:Renal Dialysis; D013296:Streptococcus pneumoniae / Q000276:immunology*
chemical_list: C538862:13-valent pneumococcal vaccine; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial